Tags

Type your tag names separated by a space and hit enter

Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
Am J Med Genet A. 2014 Aug; 164A(8):1953-64.AJ

Abstract

Mucopolysaccharidosis VI (MPS VI) is a clinically heterogeneous and progressive disorder with multiorgan manifestations caused by deficient N-acetylgalactosamine-4-sulfatase activity. A cross-sectional Survey Study in individuals (n = 121) affected with MPS VI was conducted between 2001 and 2002 to establish demographics, urinary glycosaminoglycan (GAG) levels, and clinical progression of disease. We conducted a Resurvey Study (ClinicalTrials.gov: NCT01387854) to obtain 10-year follow-up data, including medical histories and clinical assessments (n = 59), and survival status over 12 years (n = 117). Patients received a mean (SD) of 6.8 (2.2) years of galsulfase ERT between baseline (Survey Study) and follow-up. ERT patients increased in height by 20.4 cm in the 4-7-year-old baseline age group and by 16.8 cm in the 8-12-year-old baseline age group. ERT patients <13 years-old demonstrated improvement in forced vital capacity (FVC) by 68% and forced expiratory volume in 1 sec (FEV1) by 55%, and those ≥13 years-old increased FVC by 12.8% and maintained FEV1. Patients with >200 µg/mg baseline uGAG levels increased FVC by 48% in the <13-year-old baseline age group and by 15% in the ≥13-year-old baseline age group. ERT patients who completed the 6-min walk test demonstrated a mean (SD) increase of 65.7 (100.6) m. Cardiac outcomes did not significantly improve or worsen. Observed mortality rate among naïve patients was 50% (7/14) and 16.5% (17/103) in the ERT group (unadjusted hazard ratio, 0.24; 95% CI, 0.10-0.59). Long-term galsulfase ERT was associated with improvements in pulmonary function and endurance, stabilized cardiac function and increased survival.

Authors+Show Affiliations

Medical Genetics Service, HCPA, Department of Genetics, UFRGS, and INAGEMP, Porto Alegre, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24764221

Citation

Giugliani, Roberto, et al. "Natural History and Galsulfase Treatment in Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)--10-year Follow-up of Patients Who Previously Participated in an MPS VI Survey Study." American Journal of Medical Genetics. Part A, vol. 164A, no. 8, 2014, pp. 1953-64.
Giugliani R, Lampe C, Guffon N, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am J Med Genet A. 2014;164A(8):1953-64.
Giugliani, R., Lampe, C., Guffon, N., Ketteridge, D., Leão-Teles, E., Wraith, J. E., Jones, S. A., Piscia-Nichols, C., Lin, P., Quartel, A., & Harmatz, P. (2014). Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. American Journal of Medical Genetics. Part A, 164A(8), 1953-64. https://doi.org/10.1002/ajmg.a.36584
Giugliani R, et al. Natural History and Galsulfase Treatment in Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)--10-year Follow-up of Patients Who Previously Participated in an MPS VI Survey Study. Am J Med Genet A. 2014;164A(8):1953-64. PubMed PMID: 24764221.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. AU - Giugliani,Roberto, AU - Lampe,Christina, AU - Guffon,Nathalie, AU - Ketteridge,David, AU - Leão-Teles,Elisa, AU - Wraith,James E, AU - Jones,Simon A, AU - Piscia-Nichols,Cheri, AU - Lin,Ping, AU - Quartel,Adrian, AU - Harmatz,Paul, Y1 - 2014/04/24/ PY - 2013/11/01/received PY - 2014/03/16/accepted PY - 2014/4/26/entrez PY - 2014/4/26/pubmed PY - 2015/4/1/medline KW - Maroteaux-Lamy syndrome KW - N-acetylgalactosamine-4-sulfatase KW - enzyme replacement therapy KW - exercise tolerance KW - follow-up studies KW - mucopolysaccharidosis VI KW - multicenter study [publication type] KW - respiratory function tests KW - survival rate SP - 1953 EP - 64 JF - American journal of medical genetics. Part A JO - Am. J. Med. Genet. A VL - 164A IS - 8 N2 - Mucopolysaccharidosis VI (MPS VI) is a clinically heterogeneous and progressive disorder with multiorgan manifestations caused by deficient N-acetylgalactosamine-4-sulfatase activity. A cross-sectional Survey Study in individuals (n = 121) affected with MPS VI was conducted between 2001 and 2002 to establish demographics, urinary glycosaminoglycan (GAG) levels, and clinical progression of disease. We conducted a Resurvey Study (ClinicalTrials.gov: NCT01387854) to obtain 10-year follow-up data, including medical histories and clinical assessments (n = 59), and survival status over 12 years (n = 117). Patients received a mean (SD) of 6.8 (2.2) years of galsulfase ERT between baseline (Survey Study) and follow-up. ERT patients increased in height by 20.4 cm in the 4-7-year-old baseline age group and by 16.8 cm in the 8-12-year-old baseline age group. ERT patients <13 years-old demonstrated improvement in forced vital capacity (FVC) by 68% and forced expiratory volume in 1 sec (FEV1) by 55%, and those ≥13 years-old increased FVC by 12.8% and maintained FEV1. Patients with >200 µg/mg baseline uGAG levels increased FVC by 48% in the <13-year-old baseline age group and by 15% in the ≥13-year-old baseline age group. ERT patients who completed the 6-min walk test demonstrated a mean (SD) increase of 65.7 (100.6) m. Cardiac outcomes did not significantly improve or worsen. Observed mortality rate among naïve patients was 50% (7/14) and 16.5% (17/103) in the ERT group (unadjusted hazard ratio, 0.24; 95% CI, 0.10-0.59). Long-term galsulfase ERT was associated with improvements in pulmonary function and endurance, stabilized cardiac function and increased survival. SN - 1552-4833 UR - https://www.unboundmedicine.com/medline/citation/24764221/Natural_history_and_galsulfase_treatment_in_mucopolysaccharidosis_VI__MPS_VI_Maroteaux_Lamy_syndrome___10_year_follow_up_of_patients_who_previously_participated_in_an_MPS_VI_Survey_Study_ L2 - https://doi.org/10.1002/ajmg.a.36584 DB - PRIME DP - Unbound Medicine ER -